VivoSim Labs Disclosed Failure to Satisfy a Continued Listing Rule or Standard
VivoSim Labs (VIVS) received a notice from Nasdaq for failing to meet the $1.00 minimum bid price requirement. The company has 180 days to comply, considering a reverse stock split, and continues trading on the Nasdaq Capital Market.
How this was made
The 30-second read
Why it matters
The listing warning creates immediate downside pressure and uncertainty about a possible reverse split or delisting.
Market read
Primary corporate action affecting VIVS; limited spillover to similar low‑price stocks.
What to watch
Potential upcoming financing or partnership announcements that could restore price compliance.
Background
VivoSim Labs (VIVS) is a Nasdaq‑listed biotech microcap that failed the $1.00 minimum bid price rule.
Ticker impact
Nasdaq notified VivoSim Labs that its share price stayed below $1.00 for 30 days, triggering a delisting warning and possible reverse split.
Short-term downside risk; possible bounce if split is announced.
Listing non‑compliance historically leads to price declines; the 180‑day cure period adds uncertainty.
Market effects
May signal heightened compliance risk for other low‑price Nasdaq Capital Market stocks.
Limited to U.S. small‑cap investors; no broader regional effect.
Minimal global impact; only relevant to niche biotech/tech microcaps.
Counterpoint
If the company successfully executes a reverse split, the lower share count could attract institutional interest.
Key entities
- Regulatory BodyNasdaq
Issuer of the listing compliance notice.
- CompanyVivoSim Labs
Subject of the compliance notice.
